CagriSema Awaits FDA Verdict as Q4 2026 Decision Window Opens
Novo Nordisk's cagrilintide-semaglutide combination is expected to get an FDA decision before year-end, though a missed head-to-head goal against tirzepatide hangs over its prospects.
Source: Drugs.com — CagriSema Approval Status
Enlicitide Becomes First Oral PCSK9 Inhibitor, a Win for Macrocyclic Peptide Design
Merck's enlicitide (Lipfendra), a once-daily macrocyclic peptide tablet, is FDA-approved for lowering LDL cholesterol, showing engineered peptides can reach targets once reserved for injectable antibodies.
Source: TCTMD — Enlicitide FDA Approval
Medicare to Launch GLP-1 Coverage Demonstration Program in July 2026
CMS announces a new payment demonstration that will provide Medicare beneficiaries with access to GLP-1 medications for obesity, bridging to the full BALANCE Model in 2027.
Source: CMS.gov
14 Peptides Including BPC-157 and TB-500 Reclassified Back to Legal Compounding Status
HHS Secretary Kennedy announces that 14 previously restricted peptides will return to Category 1, restoring access through compounding pharmacies with a prescription.
Source: Peptibase
Daily Briefing
Get the latest peptide research delivered to your inbox every morning.
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.